<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044598</url>
  </required_header>
  <id_info>
    <org_study_id>CTU/2017/307</org_study_id>
    <nct_id>NCT05044598</nct_id>
  </id_info>
  <brief_title>RAFT - Clinical Trial of RAFT for Aniridia Related Keratopathy</brief_title>
  <acronym>RAFT</acronym>
  <official_title>RAFT - First in Human Phase I/II Clinical Trial of RAFT for Aniridia Related Keratopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moorfields Eye Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RAFT trial is a first in human trial of a novel cellular therapy called RAFT-OS (Real&#xD;
      Architecture for 3D Tissues Ocular Surface) developed and manufactured by Cells for Sight&#xD;
      Stem Cell Therapy Research Unit at UCL institute of Ophthalmology. The aim of the trial is to&#xD;
      investigate if RAFT-OS is a safe and effective alternative treatment for patients with&#xD;
      aniridia related keratopathy (ARK) in 21 patients. ARK is a complication of aniridia, which&#xD;
      is a genetic eye condition present from birth. RAFT-OS is an artificial tissue, populated&#xD;
      with limbal epithelial cells and stromal cells. The source of the adult limbal and stromal&#xD;
      cells is from donated human corneas from the NHS blood and Transplant, Tissue and Eye&#xD;
      services Liverpool. Participants will commence on 3 months of immune suppression therapy to&#xD;
      prepare for the transplantation of RAFTOS.&#xD;
&#xD;
      The product will then be transplanted into the participants worst affected eye. Following&#xD;
      surgery participants will be allowed to go home the following day, after the day 1 eye&#xD;
      examination. Participants will then be followed up closely for the first 4 weeks following&#xD;
      surgery for signs of infection or other complications. If there are no serious events, the&#xD;
      next participant will be treated with RAFT-OS. The trial team will regularly follow&#xD;
      participants after transplantation for 12 months, with detailed review of symptoms,&#xD;
      investigations such as digital photography of the eye and examinations of the surface of the&#xD;
      eye.&#xD;
&#xD;
      Participants will be required to stay on the immune suppression therapy for the duration of&#xD;
      the trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as occurrence of intermediate and major safety events in the RAFT protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>3 months</time_frame>
    <description>defined as corneal surface normalisation at 3 months post RAFT-OS surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Improvement</measure>
    <time_frame>3 &amp; 12 months post RAFT transplantation</time_frame>
    <description>Visual Improvement assessed by visual acuity (with correction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life</measure>
    <time_frame>at 3 &amp; 12 months post RAFT transplantation</time_frame>
    <description>as assessed by NEI-VFQ-25 patient questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of Life</measure>
    <time_frame>3 &amp;12 months post RAFT transplantation.</time_frame>
    <description>RAND 36-Item Health Survey.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Aniridia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RAFT-OS</intervention_name>
    <description>RAFT-OS is an artificial tissue, populated with limbal epithelial cells and stromal cells.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of congenital aniridia&#xD;
&#xD;
          2. Confirmed diagnosis of advanced aniridia related keratopathy with corneal surface&#xD;
             conjunctivalisation, vascularisation and increasing opacity with worsening vision&#xD;
             loss, glare &amp; ocular surface pain&#xD;
&#xD;
          3. Patients aged 18 years and over&#xD;
&#xD;
          4. Participants must use acceptable contraception from enrolment up to 6 weeks for female&#xD;
             participants and 90 days for male participants, after stopping immunosuppression&#xD;
             therapy&#xD;
&#xD;
          5. Negative viral screen for, HIV, syphilis, hepatitis B &amp; C and Human T-cell Leukaemia&#xD;
             Virus (HTLV)&#xD;
&#xD;
          6. Negative urine pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Poor tear production, as assessed by a Schirmer's test type 1&#xD;
&#xD;
          2. Lid malposition&#xD;
&#xD;
          3. Current corneal infection&#xD;
&#xD;
          4. Uncontrolled glaucoma (defined as uncontrolled eye pressure, changes to medication,&#xD;
             recent surgery in the last 3 months or being considered for surgical treatment)&#xD;
&#xD;
          5. Must not be NPL (no light perception) in one or both eyes&#xD;
&#xD;
          6. Patients who refuse to consent to the site informing their GP of their participation&#xD;
&#xD;
          7. Patients who lack capacity to give full informed consent to participate&#xD;
&#xD;
          8. Pregnant or lactating women&#xD;
&#xD;
          9. Patients with known contraindications to any of the following non-investigational&#xD;
             medicinal productsÍ¾ mycophenolate, prednisolone, omeprazole, doxycycline,&#xD;
             dexamethasone &amp; moxifloxacin&#xD;
&#xD;
         10. Patients who are participating in any concurrent trial involving an investigational&#xD;
             medical product, device or surgical intervention within the last 12 months&#xD;
&#xD;
         11. Known albumin or egg allergy&#xD;
&#xD;
         12. Known penicillin allergy&#xD;
&#xD;
         13. Known hydrocortisone allergy&#xD;
&#xD;
         14. Inability to lie flat for surgical procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jade Dyer</last_name>
    <phone>020 7907 4674</phone>
    <email>raft@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liz Dean</last_name>
    <email>raft@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Facility</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials Unit</name>
      <address>
        <city>London</city>
        <zip>WC1V 6LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Gruenwald</last_name>
      <email>raft@ucl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Liz Deane</last_name>
      <email>raft@ucl.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Sajjad Ahmad</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Daniels</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aniridia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

